Other languages ABVC BioPharma, Inc.

Equities

ABVC

US00091F3047

Real-time Estimate Cboe BZX Other stock markets 15:03:22 01/05/2024 BST			5-day change	1st Jan Change
1.145 ^USD	-8.40%		-18.93%	+3.44%

04-10	ABVC BioPharma, Inc., BioLite, Inc. and Rgene Corporation Enter Term Sheet with OncoX BioPharma, Inc	CI
03-26	ABVC BioPharma, Inc. and BioFirst Corporation Enter Global Licensing Agreement with ForSeeCon Eye Corporation	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

ABVC BioPharma, Inc., BioLite, Inc. and Rgene Corporation Enter Term Sheet with OncoX BioPharma, Inc	04-10
ABVC BioPharma, Inc. and BioFirst Corporation Enter Global Licensing Agreement with ForSeeCon Eye Corporation	03-26
ABVC BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-13
ABVC BioPharma Signs Licensing Deal With Senior Paradise	02-15
ABVC BioPharma, Inc. Executes a Definitive Agreement to Receive License Fees of $3 Million and Royalties of 2% on Future Revenue	02-15
Top Premarket Decliners	01-04
Sector Update: Health Care Stocks Mixed Late Afternoon	01-03
Sector Update: Health Care	01-03
Traders Anticipate Fed Minutes as US Equity Futures Decline Pre-Bell	01-03
Top Midday Gainers	01-03
ABVC BioPharma, Inc. Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study	12-07
ABVC BioPharma, Inc. Enters Definitive Agreement with Licensing Income Worth $467 Million and Royalties Up to $200 Million	11-16
ABVC BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-15
Wall Street Set to Open Lower as GDP, Jobless Claims Higher Than Expected	26/10/23
ABVC BioPharma Enters Into a Term Sheet to License Global Rights of CNS Drugs with the Indications of MDD and ADHD to AiBtl BioPharma at the Valuation of $667 Million	26/10/23
Abvc Biopharma, Inc. Announces Completion of Subject Recruitment for Interim Analysis on Adhd Phase Iib Clinical Study	17/10/23
Top Premarket Gainers	15/09/23
ABVC BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	14/08/23
ABVC BioPharma, Inc. Announces the Approval of the Plan for GMP Production Facilities of Vitargus by Taiwan Science Park Administration	03/08/23
Top Midday Gainers	01/08/23

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages ABVC BioPharma, Inc.

Equities

ABVC

US00091F3047

Other languages

Filters